Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Phenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazine SCHEMBL8564741 | 0.89 | MAPT (0.65) | MAPTCYP1A2CYP2D6CYP2C9CASP1 | |
| Phenazine SCHEMBL2923781 | 0.89 | MAPT (0.65) | MAPTCYP1A2CYP2D6CYP2C9CASP1 | |
| Phenazine SCHEMBL28658053 | 0.87 | MAPT (0.55) | MAPTCYP1A2CYP2D6CYP2C9CASP1 | |
| Phenazine SCHEMBL28835271 | 0.86 | MAPT (0.61) | MAPTCYP1A2CYP2D6CYP2C9CASP1 | |
| Acridine SCHEMBL8000372 | 0.86 | ALDH1A1 (0.65) | MAPTCYP1A2CYP2D6CYP2C9CASP1 | |
| Phenazine SCHEMBL23522712 | 0.84 | MAPT (0.58) | MAPTCYP1A2CYP2D6CYP2C9CASP1 | |
| Phenazine SCHEMBL23522711 | 0.84 | MAPT (0.58) | MAPTCYP1A2CYP2D6CYP2C9CASP1 | |
| Phenazine SCHEMBL2873102 | 0.83 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CASP1 | |
| Phenazine SCHEMBL94396 | 0.83 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CASP1 | |
| Phenazine SCHEMBL10876543 | 0.83 | MAPT (0.50) | MAPTCYP1A2CYP2D6CYP2C9CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| CN-108350438-B | Novel glucose dehydrogenase | 天野酶株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-7968736-B2 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | University of Pittsburgh—of the Commonwelth Systems of Higher Education (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090036691-A1 | ANALOGS OF DICODERMOLIDE AND DICTYOSTATIN-1, INTERMEDIATES THEREFOR AND METHODS OF SYNTHESIS THEREOF | PITTSBURGH UNIVERSITY OF - OF THE COMMONWEALTH SYSTEM OF HIGHER | 2009-02-05 | — | — | US | disclosed |
| CN-101265299-A | Biologically active peptides from functional domains of bactericidal permeability-increasing protein and uses thereof | XOMA CORP (US) | 2008-09-17 | — | — | CN | disclosed |
| CN-100396695-C | Bioactive peptides from functional domains of bactericidal permeability-increasing proteins and uses thereof | XOMA CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| US-20060270862-A1 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | PITTSBURGH, UNIVERSITY OF | 2006-11-30 | — | — | US | disclosed |
| US-7122686-B2 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | UNIVERSITY OF PITTSBURGH (US) | 2006-10-17 | — | — | US | disclosed |
| US-7045500-B2 | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | XOMA TECHNOLOGY LTD. (BM) | 2006-05-16 | — | — | US | disclosed |
| US-20040186165-A1 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-09-23 | — | — | US | disclosed |
| EP-0690872-B1 | BIOLOGICALLY ACTIVE PEPTIDES FROM FUNCTIONAL DOMAINS OF BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN AND USES THEREOF | XOMA CORP (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5763567-A | HUMAN AMINO ACID SEQUENCES WHICH CAN BIND TO AND/OR NEUTRALIZE HEPARIN | XOMA CORPORATION (US) | 1998-06-09 | — | — | US | disclosed |
| US-5733872-A | BACTERICIDES | XOMA CORPORATION (US) | 1998-03-31 | — | — | US | disclosed |
| US-5652332-A | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | XOMA (US) | 1997-07-29 | — | — | US | disclosed |
| CN-1141637-A | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | XOMA CORP (US) | 1997-01-29 | — | — | CN | disclosed |
| EP-0754194-A1 | BIOLOGICALLY ACTIVE PEPTIDES FROM FUNCTIONAL DOMAINS OF BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN AND USES THEREOF | Xoma Corporation (US) | 1997-01-22 | — | — | EP | disclosed |
| CN-1122602-A | Bioactive peptides from functional domains of bactericidal permeability-increasing proteins and uses thereof | XOMA CORP (US) | 1996-05-15 | — | — | CN | disclosed |
| EP-0690872-A1 | BIOLOGICALLY ACTIVE PEPTIDES FROM FUNCTIONAL DOMAINS OF BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN AND USES THEREOF | Xoma Corporation (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1995019372-A1 | BIOLOGICALLY ACTIVE PEPTIDES FROM FUNCTIONAL DOMAINS OF BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN AND USES THEREOF | XOMA CORPORATION (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1994020532-A1 | BIOLOGICALLY ACTIVE PEPTIDES FROM FUNCTIONAL DOMAINS OF BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN AND USES THEREOF | XOMA CORPORATION (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036691-A1 | ANALOGS OF DICODERMOLIDE AND DICTYOSTATIN-1, INTERMEDIATES THEREFOR AND METHODS OF SYNTHESIS THEREOF | RRS1, RPS3A, RPS3 | MAPT 4882/4885CYP1A2 3270/4885CYP2D6 3576/4885 |
| US-20060270862-A1 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | RRS1, RPS6KA3, RPS6KA4 | MAPT 4879/4885CYP1A2 3987/4885CYP2D6 4014/4885 |
| US-20040186165-A1 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | DECR1, RRS1, WEE1 | MAPT 4814/4885CYP1A2 4195/4885CYP2D6 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.